{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:11:26Z","timestamp":1760299886845,"version":"build-2065373602"},"reference-count":63,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,6]],"date-time":"2006-07-06T00:00:00Z","timestamp":1152144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radioimmunotherapy (RIT) with Yttrium\u201090 (<jats:sup>90<\/jats:sup>Y) ibritumomab tiuxetan (Zevalin\u00ae) combines the tumor targeting attributes of a monoclonal antibody against the CD20 antigen and the pure \u03b2\u2010radiation of <jats:sup>90<\/jats:sup>Y. High efficacy and a favorable safety profile have been demonstrated in Phase II and III clinical trials enrolling patients with CD20<jats:sup>+<\/jats:sup> B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL). On the basis of these results, <jats:sup>90<\/jats:sup>Y\u2010ibritumomab tiuxetan was approved in the United States for the treatment of patients with follicular lymphoma (FL) or transformed B\u2010NHL. In the European Union its use was restricted to FL, refractory to or relapsed after rituximab. There are a number of important clinical trials currently evaluating <jats:sup>90<\/jats:sup>Y\u2010ibritumomab tiuxetan in other subtypes of lymphoma such as diffuse large\u2010cell and mantle\u2010cell lymphoma, as consolidation therapy or as part of myeloablative regimens. In light of the constantly increasing clinical experience with RIT, clinicians face the challenge of how to best integrate this promising new treatment option into existing established treatment algorithms. By incorporating the most recent data in this rapidly developing field, this review article focuses on current recommendations for the use of <jats:sup>90<\/jats:sup>Y\u2010ibritumomab tiuxetan in patients with malignant lymphoma, outlines future perspectives, and provides practical recommendations for patient management. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.22066","type":"journal-article","created":{"date-parts":[[2006,7,6]],"date-time":"2006-07-06T17:18:28Z","timestamp":1152206308000},"page":"686-695","source":"Crossref","is-referenced-by-count":24,"title":["Recommendations for the use of Yttrium\u201090 ibritumomab tiuxetan in malignant lymphoma"],"prefix":"10.1002","volume":"107","author":[{"given":"Oliver","family":"Weigert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Illidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,8,10]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.2.74"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.53.1.5"},{"volume-title":"Tumours of the Haemopoitic and Lymphoid Tissues","year":"2001","author":"Jaffe ES","key":"e_1_2_9_4_2"},{"issue":"5","key":"e_1_2_9_5_2","first-page":"75","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin's lymphomas","volume":"20","author":"Horning SJ","year":"1993","journal-title":"Semin Oncol."},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0982"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.016"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/09553008214550451"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(00)00167-5"},{"issue":"4","key":"e_1_2_9_16_2","first-page":"10","article-title":"Radioimmunotherapy for non\u2010Hodgkin's lymphomas: A historical perspective","volume":"30","author":"Press OW","year":"2003","journal-title":"Semin Oncol."},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.6.1424.1424"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.2.584.584"},{"key":"e_1_2_9_19_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4049\/jimmunol.135.2.973","article-title":"The B cell surface molecule B1 is functionally linked with B cell activation and differentiation","volume":"135","author":"Tedder TF","year":"1985","journal-title":"J Immunol."},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe048291"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.3.3.157"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2.5.485"},{"key":"e_1_2_9_24_2","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non\u2010Hodgkin's lymphoma with 90Y\u2010labeled anti\u2010CD20 monoclonal antibody","volume":"43","author":"Wagner HN","year":"2002","journal-title":"J Nucl Med."},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4336"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"e_1_2_9_29_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood.V104.11.130.130","article-title":"Yttrium\u201090 ibritumomab tiuxetan (Zevalin) for patients with relapsed\/refractory diffuse large cell b\u2010cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open\u2010label phase II trial","volume":"104","author":"Morschhauser F","year":"2004","journal-title":"Blood."},{"issue":"11","key":"e_1_2_9_30_2","article-title":"Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL)","volume":"106","author":"Younes A","year":"2005","journal-title":"Blood."},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10305"},{"issue":"16","key":"e_1_2_9_32_2","article-title":"Localization of Yttrium 90 ibritumomab tiuxetan (90Y IT) in patients with CD20+ non\u2010Hodgkin's lymphoma","volume":"23","author":"Jacobs SA","year":"2005","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_9_33_2","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y\u2010ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non\u2010Hodgkin's lymphoma: Combined data from 4 clinical trials","volume":"44","author":"Wiseman GA","year":"2003","journal-title":"J Nucl Med."},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00107-X"},{"issue":"10","key":"e_1_2_9_35_2","first-page":"S3281","article-title":"Radioimmunotherapy of relapsed non\u2010Hodgkin's lymphoma with Zevalin, a 90Y\u2010labeled anti\u2010CD20 monoclonal antibody","volume":"5","author":"Wiseman GA","year":"1999","journal-title":"Clin Cancer Res."},{"issue":"16","key":"e_1_2_9_36_2","article-title":"Experience with 90Yttrium ibritumomab tiuxetan (Zevalin\u00ae) after autologous stem cell transplant (asct) in patients with non\u2010Hodgkin's lymphoma (NHL)","volume":"23","author":"Joyce J","year":"2005","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.043"},{"issue":"11","key":"e_1_2_9_38_2","article-title":"Zevalin is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)","volume":"100","author":"Czuczman M","year":"2002","journal-title":"Blood"},{"key":"e_1_2_9_39_2","first-page":"1198","article-title":"Radiation exposure is very low to the family members of patients treated with yttrium\u201090 Zevalin anti\u2010CD20 monoclonal antibody therapy for lymphoma","volume":"28","author":"Wiseman G","year":"2001","journal-title":"Eur J Nucl Med."},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00108-1"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3883"},{"issue":"11","key":"e_1_2_9_42_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2448.2448","article-title":"A phase I study of 90Y\u2010ibritumomab\u2010tiuxetan (90Y\u2010It) in children with recurrent\/refractory CD20 positive lymphoma: A cog phase I consortium study","volume":"106","author":"Cairo MS","year":"2005","journal-title":"Blood"},{"issue":"2","key":"e_1_2_9_43_2","first-page":"S8","article-title":"Earlier yttrium\u201090 ibritumomab tiuxetan (Zevalin) treatment in patients with previously\u2010treated B\u2010cell non\u2010Hodgkin's lymphoma: Higher response rates and longer durations of response","volume":"5","author":"Emmanouilides C","year":"2004","journal-title":"Hematol J."},{"issue":"11","key":"e_1_2_9_44_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.2633.2633","article-title":"Efficacy and safety of yttrium\u201090 (90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low\u2010grade follicular lymphoma","volume":"104","author":"Sweetenham JW","year":"2004","journal-title":"Blood"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.143"},{"issue":"2","key":"e_1_2_9_46_2","first-page":"S7","article-title":"Subsequent therapy for non\u2010Hodgkin's lymphoma is feasible after radioimmunotherapy with yttrium\u201090 ibritumomab tiuxetan (Zevalin)","volume":"5","author":"Schilder RJ","year":"2004","journal-title":"Hematol J."},{"key":"e_1_2_9_47_2","article-title":"Yttrium\u201090 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B\u2010cell lymphoma (NHL): Preliminary results","volume":"100","author":"Wiseman G","year":"2002","journal-title":"Blood"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2004.1.203"},{"issue":"11","key":"e_1_2_9_49_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.4786.4786","article-title":"Efficacy and safety of a single\u2010course of yttrium\u201090 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) in patients with relapsed or refractory mantle cell lymphoma (mcl) after\/ not appropriate for autologous stem cell transplantation (asct)\u2010 A phase II trial of the European mcl network","volume":"106","author":"Weigert O","year":"2005","journal-title":"Blood."},{"issue":"16","key":"e_1_2_9_50_2","article-title":"Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first\u2010line treatment for patients with follicular lymphoma: Update of a minnie pearl cancer res network phase II trial","volume":"23","author":"Shipley DL","year":"2005","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_9_51_2","article-title":"Ibritumomab tiuxetan (Zevalin TM) therapy is feasible and safe for the treatment of patients with advanced B\u2010cell follicular lymphoma: Interim analysis for safety of a multicenter, phase III clinical trial","volume":"102","author":"Radford JA","year":"2003","journal-title":"Blood."},{"issue":"11","key":"e_1_2_9_52_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2449.2449","article-title":"Phase II trial of abbreviated chop\u2010rituximab followed by 90Y ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously\u2010untreated follicular non\u2010Hodgkin lymphoma (NHL)","volume":"106","author":"DeMonaco NA","year":"2005","journal-title":"Blood."},{"issue":"11","key":"e_1_2_9_53_2","article-title":"A Phase II trial of fm (oral fludarabine and mitoxantrone) chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for previously untreated follicular lymphoma (FL) patients","volume":"106","author":"Zinzani PL","year":"2005","journal-title":"Blood."},{"issue":"11","key":"e_1_2_9_54_2","article-title":"A phase II trial of chop chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (zevalin) for previously untreated elderly diffuse large B\u2010cell lymphoma (DLBCL) patients","volume":"106","author":"Zinzani PL","year":"2005","journal-title":"Blood."},{"issue":"11","key":"e_1_2_9_55_2","article-title":"Consolidation of chemotherapy response in mantle cell lymphoma (MCL) patients with 90Y\u2010ibritumomab tiuxetan (90Y\u2010Zevalin) radioimmunotherapy (RIT)","volume":"106","author":"Jurczak W","year":"2005","journal-title":"Blood."},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310213291702"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0622"},{"key":"e_1_2_9_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2934"},{"issue":"11","key":"e_1_2_9_59_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.897.897","article-title":"Dose finding trial of yttrium 90 (90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B\u2010cell non\u2010Hodgkins lymphoma (NHL)","volume":"104","author":"Flinn IW","year":"2004","journal-title":"Blood."},{"key":"e_1_2_9_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1310"},{"issue":"11","key":"e_1_2_9_61_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.1162.1162","article-title":"90Y ibritumomab tiuxetan (Zevalin, 90YZ) doses higher than 0.4 mCi\/kg may be safely combined with high\u2010dose BEAM and autotransplant: The role of dosimetry","volume":"104","author":"Winter JN","year":"2004","journal-title":"Blood."},{"issue":"16","key":"e_1_2_9_62_2","article-title":"The outcome of ABEAM, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non\u2010Hodgkin's lymphoma","volume":"23","author":"Krishnan AY","year":"2005","journal-title":"Proc Am Soc Clin Oncol."},{"issue":"11","key":"e_1_2_9_63_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.1131.1131","article-title":"Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced\u2010intensity allogeneic stem\u2010cell transplantation in patients with chemo\u2010refractory non\u2010Hodgkin's lymphoma","volume":"106","author":"Shimoni A","year":"2005","journal-title":"Blood."},{"issue":"11","key":"e_1_2_9_64_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.488.488","article-title":"High dose Zevalin (90Yttrium ibritumomab tiuxetan) Treatment with PBSC support in refractory\u2010resistant NHL patients: Preliminary results of a phase I\/II study","volume":"106","author":"Vanazzi A","year":"2005","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22066","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:35:58Z","timestamp":1760297758000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,10]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8,15]]}},"alternative-id":["10.1002\/cncr.22066"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22066","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2006,8,10]]}}}